Clinical Trial Update: The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation [Phase 2]

View source ↗

Summary

Phase 2 study evaluating olaparib in newly diagnosed metastatic castration-resistant prostate cancer patients with HRR gene mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Olaparib (Olaparib)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Prostate Cancer, Prostate Carcinoma | Phase 2 | Status: UNKNOWN